Earnings call transcript: Thomson Reuters sees strong Q1 2026 growth, stock dips

Thomson Reuters reported solid Q1 2026 results, with 8% organic revenue growth, adjusted EPS up 10% to $1.23, adjusted EBITDA up 9% to $881 million, and free cash flow up 19% to $332 million. Management reaffirmed full-year 2026 guidance for 7.5%-8% organic revenue growth, about 40% EBITDA margins, and roughly $2.1 billion of free cash flow, while highlighting accelerating AI adoption with GenAI-enabled ACV rising to 30%. Shares fell 3.92% to $121.96 despite the beat, as investors remained cautious amid print revenue declines, lower analyst estimates, and broader market volatility.

Analysis

The market is still pricing TRI like a melting-content utility, while management is trying to re-rate it as a compounder with embedded software optionality. The key second-order effect is that AI is not just lifting ARPU; it is widening the product surface area and lowering churn by making the suite stickier across legal, tax, and compliance workflows. That matters because if AI adoption keeps migrating from experimentation into daily habit, revenue acceleration can persist even with modest seat expansion, and the valuation gap versus software peers becomes harder to justify.

The near-term dislocation looks partly mechanical. The stock’s move suggests investors are discounting the transition costs — LLM expense, acquisition dilution, and execution risk around the new CFO/next-gen launches — while underweighting the fact that TR can fund AI development with cash flow and capital returns rather than balance-sheet strain. In other words, the incremental dollars spent on model access may be a feature, not a bug, if they shorten sales cycles and deepen wallet share before proprietary models fully offset third-party costs.

Consensus is likely missing the duration of the legal workflow replacement cycle. Management’s commentary implies this is not a one-quarter upgrade story but a multi-year conversion of billable professional time into software spend; that creates a longer runway than the current estimates imply. The main downside is if AI adoption stalls at the pilot stage and customer trials cap out before procurement standardization, but the accelerating usage data argues the burden of proof is shifting toward bears.

Near term, the biggest catalyst is not Q2 revenue but evidence that CoCounsel next converts interest into recognized ARR in 2H26 and that government/legal ex-government retention stabilizes. If those two line items inflect together, the stock can move quickly because the current multiple likely embeds little credit for a durable 2027 step-up. Conversely, if product adoption remains strong but monetization lags, the de-rating can persist another 1-2 quarters.

Key Decisions for Investors

• Go long TRI on a 3-6 month horizon; use weakness below the post-earnings level as entry. Risk/reward favors 15-25% upside if the market starts capitalizing AI-enabled ACV and next-gen CoCounsel revenue, versus limited downside if guidance holds.
• Buy TRI Jan-2027 call spreads to express the 2027 monetization inflection without overpaying for near-term noise. Structure for upside tied to the revenue recognition ramp from CoCounsel next and margin expansion from lower unit AI costs.
• Pair trade: long TRI / short a basket of slower-moving legal-services or document-workflow names that lack proprietary content and domain-specific data moats. The thesis is TRI keeps widening its moat while generic AI exposure gets commoditized.
• For existing TRI longs, hedge the next 1-2 quarters with short-dated puts into the Q2 print if you worry about timing risk. The risk is not fundamental collapse but that recognition of AI monetization lags usage and keeps sentiment depressed.
• Monitor for a break above prior resistance only after management proves that AI-driven adoption is translating into 2H26 booked revenue, not just engagement metrics. If that happens, add aggressively; if not, keep sizing modest and treat it as a trading compounder rather than a core all-clear.